ישראל - עברית - Ministry of Health

neopharm (israel) 1996 ltd - rilonacept - אבקה מיובשת בהקפאה להכנת תמיסה להזרקה - rilonacept 80 mg/ml - rilonacept

ישראל - עברית - Ministry of Health

neopharm (israel) 1996 ltd - rilonacept - אבקה מיובשת בהקפאה להכנת תמיסה להזרקה - rilonacept 80 mg/ml - rilonacept

ישראל - עברית - Ministry of Health

sanofi israel ltd - cemiplimab - תרכיז להכנת תמיסה לאינפוזיה - cemiplimab 50 mg / 1 ml - cemiplimab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab - rituximab - mabthera is indicated for the following indications: * non-hodgkin’s lymphoma (nhl)mabthera is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, b-cell non-hodgkin’s lymphoma.mabthera is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy mabthera is indicated for the treatment of patients with cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop chemotherapy. mabthera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * chronic lymphocytic leukaemia (cll)mabthera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including mabthera or patients refractory to previous mabthera plu

ישראל - עברית - Ministry of Health

נוגם תמרוקים בעמ - לחות לפנים

ישראל - עברית - Ministry of Health

נוגם תמרוקים בעמ - הזנה לפנים

ישראל - עברית - Ministry of Health

אנה לוטן בעמ - העשרת עור יבש בויטמינים

ישראל - עברית - Ministry of Health

ת.י דרמל גרופ (2009) בעמ - טיפוח עור הפנים

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - אבקה וממס להכנת תמיסה להזרקה - etanercept 25 mg/vial - etanercept - etanercept - * rheumatoid arthritis:enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* polyarticular juvenile idiopathic arthritis: treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. enbrel has not been studied in children aged less than 2 years.* psoriatic arthritistreatment of ac

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - תמיסה להזרקה - etanercept 50 mg/ml - etanercept - etanercept - * rheumatoid arthritis:enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* polyarticular juvenile idiopathic arthritis: treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. enbrel has not been studied in children aged less than 2 years.* psoriatic arthritistreatment of ac